Director
Ultragenyx Pharmaceutical
Director, Clinical Pharmacology
Ultragenyx Pharmaceutical, Inc.
Dr. Hung-Liang Ezra Tai or Ezra Tai is Director in Clinical Pharmacology at Ultragenyx where he serves as a Clinical Pharmacology lead for setrusumab and other programs. He has over 20 years of experience in the pharmaceutical and biotechnology industry, serving in roles of increasing responsibility at Roche, XenoPort, Novartis, and most recently, ChemoCentryx. His experience spans from drug discovery through preclinical and clinical development, and he has worked on small molecules and protein therapeutics in a variety of disease areas. He authored sections of the avacopan (Tavneos®) NDA, which was approved by FDA in October 2021, and he contributed to the successful NDA package for gapapentin-enacarbil (Horizant). He earned a PhD in Pharmacology and Toxicology from SUNY Buffalo and completed a post-doctoral fellowship at St. Jude Children’s Research Hospital where his work contributed to the knowledge of TPMT genetic polymorphism, a key enzyme of mercaptopurine metabolism. While working full-time at XenoPort, he completed an executive master’s program in pharmacometrics from the University of Maryland.